Filing Details

Accession Number:
0001140361-14-025611
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-06-13 16:16:21
Reporting Period:
2014-06-11
Filing Date:
2014-06-13
Accepted Time:
2014-06-13 16:16:21
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1428522 Radius Health Inc. RDUS Blank Checks (6770) 800145732
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1575748 Katherine Priestley Suite 6, Albion Riverside Building
8 Hester Road
London X0 SW11 4AX
No No Yes No
1575753 Ltd Capital F2 3Rd Floor, Geneve Place, Waterfront Dr
Po Box 3175, Road Town
Tortola D8
No No Yes No
1600630 L.p. Iv Bioscience F2 Po Box 309, Ugland House
South Church Street
George Town E9 KY1-1104
No No Yes No
1600632 Ltd. Gp Iv Bioscience F2 Po Box 309, Ugland House
South Church Street
George Town E9 KY1-1104
No No Yes No
1600634 L.p. V Ventures Bio F2 Kingston Chambers, P.o. Box 173
Road Town
Tortola D8
No No Yes No
1600635 Ltd. Gp Ventures Bio F2 Kingston Chambers, P.o. Box 173
Road Town
Tortola D8
No No Yes No
1600769 Ltd Holdings Globeways 3Rd Floor, Geneve Place, Waterfront Dr
Po Box 3175, Road Town
Tortola D8
No No Yes No
1610441 L.p. Vi Bioscience F2 Po Box 309, Ugland House
South Church Street
George Town E9 KY1-1104
No No Yes No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2014-06-11 1,794,983 $0.00 1,794,983 No 4 C Direct
Common Stock Acquisiton 2014-06-11 871,851 $0.00 871,851 No 4 C Indirect See footnote
Common Stock Acquisiton 2014-06-11 587,500 $8.00 587,500 No 4 P Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 C Indirect See footnote
No 4 P Indirect See footnote
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series B-2 Convertible Preferred Stock Disposition 2014-06-11 227,938 $0.00 1,794,983 $0.00
Common Stock Series B-2 Convertible Preferred Stock Disposition 2014-06-11 110,713 $0.00 871,851 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Direct
0 No 4 C Indirect
Footnotes
  1. The securities reported reflect (i) the total number of shares of common stock issued pursuant to the conversion of Series B-2 Convertible Preferred Stock (the "Series B-2 Stock") previously reported, (ii) a 1 for 2.28 reverse stock split, effected by the Issuer on 4/24/14 (the "Stock Split"), and (iii) all accrued dividends on the Series B-2 Stock paid in shares of common stock in connection with such conversion.
  2. The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 IV. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  3. The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  4. The reported securities are owned directly by F2 Bioscience VI L.P. ("F2 Science"). F2 IV GP is the General Partner of F2 Science. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
  5. Prior to its automatic conversion into common stock upon the closing of the Issuer's initial public offering on June 11, 2014 (the "Closing Date"), the Series B-2 Stock was convertible at any time, at the holder's election and had no expiration date. On the Closing Date, the Series B-2 Stock was automatically converted into common stock on a 4.386 to 1 basis (which conversion ratio is reflective of the Stock Split), plus accrued dividends on the Series B-2 Stock payable in shares of common stock in connection with such conversion.